238 related articles for article (PubMed ID: 28658199)
1. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.
Taber DJ; Su Z; Fleming JN; McGillicuddy JW; Posadas-Salas MA; Treiber FA; Dubay D; Srinivas TR; Mauldin PD; Moran WP; Baliga PK
Transplantation; 2017 Dec; 101(12):2931-2938. PubMed ID: 28658199
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
3. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients.
Taber DJ; Gebregziabher MG; Srinivas TR; Chavin KD; Baliga PK; Egede LE
Pharmacotherapy; 2015 Jun; 35(6):569-77. PubMed ID: 26011276
[TBL] [Abstract][Full Text] [Related]
4. Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients.
Taber DJ; Hamedi M; Rodrigue JR; Gebregziabher MG; Srinivas TR; Baliga PK; Egede LE
Transplantation; 2016 Jul; 100(7):1550-7. PubMed ID: 26425875
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
6. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study.
Taber DJ; Su Z; Fleming JN; Pilch NA; Morinelli T; Mauldin P; Dubay D
Transpl Int; 2019 Jan; 32(1):84-94. PubMed ID: 30176087
[TBL] [Abstract][Full Text] [Related]
7. Patterns in Tacrolimus Variability and Association with
Piburn KH; Sigurjonsdottir VK; Indridason OS; Maestretti L; Patton MV; McGrath A; Palsson R; Gallo A; Chaudhuri A; Grimm PC
Clin J Am Soc Nephrol; 2022 Aug; 17(8):1194-1203. PubMed ID: 35882506
[TBL] [Abstract][Full Text] [Related]
8. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients.
Taber DJ; Douglass K; Srinivas T; McGillicuddy JW; Bratton CF; Chavin KD; Baliga PK; Egede LE
Am J Nephrol; 2014; 40(1):19-28. PubMed ID: 24969370
[TBL] [Abstract][Full Text] [Related]
9. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation.
Shuker N; Shuker L; van Rosmalen J; Roodnat JI; Borra LC; Weimar W; Hesselink DA; van Gelder T
Transpl Int; 2016 Nov; 29(11):1158-1167. PubMed ID: 27188932
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
11. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.
Jacobson PA; Oetting WS; Brearley AM; Leduc R; Guan W; Schladt D; Matas AJ; Lamba V; Julian BA; Mannon RB; Israni A;
Transplantation; 2011 Feb; 91(3):300-8. PubMed ID: 21206424
[TBL] [Abstract][Full Text] [Related]
12. Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients.
Taber DJ; Gebregziabher M; Srinivas T; Egede LE; Baliga PK
Ann Transplant; 2018 Feb; 23():119-128. PubMed ID: 29449524
[TBL] [Abstract][Full Text] [Related]
13. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
Soliman KM; Posadas Salas AC; Taber DJ
Exp Clin Transplant; 2019 Dec; 17(6):707-713. PubMed ID: 30570456
[TBL] [Abstract][Full Text] [Related]
14. Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol.
Goldsmith PM; Bottomley MJ; Okechukwu O; Ross VC; Ghita R; Wandless D; Falconer SJ; Papachristos S; Nash P; Androshchuk V; Clancy M;
BMJ Open; 2017 Jul; 7(7):e016144. PubMed ID: 28756385
[TBL] [Abstract][Full Text] [Related]
15. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
[TBL] [Abstract][Full Text] [Related]
16. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients.
Taber DJ; Hunt KJ; Gebregziabher M; Srinivas T; Chavin KD; Baliga PK; Egede LE
Clin J Am Soc Nephrol; 2017 Jan; 12(1):131-139. PubMed ID: 27979979
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: a retrospective analysis.
Palanisamy AP; Schiltz CE; Pilch NA; Hunt KJ; Nadig SN; Dowden JE; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
Blood Press; 2015 Feb; 24(1):14-22. PubMed ID: 25048253
[TBL] [Abstract][Full Text] [Related]
19. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial.
McGillicuddy JW; Chandler JL; Sox LR; Taber DJ
Ann Pharmacother; 2020 Dec; 54(12):1185-1193. PubMed ID: 32506922
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
